Shire says Fosrenol shows effective phosphate control

By Elaine Rigoli

Tampa, Fla., July 18 - Shire plc announced new data that showed calcium-free Fosrenol (lanthanum carbonate) further reduces phosphate levels in dialysis patients previously receiving other monotherapies or combined phosphate binders, including calcium carbonate and sevelamer hydrochloride.

Data also suggests that Fosrenol significantly increased the number of patients achieving Kidney Disease Outcome Quality Initiative (K/Doqi) targets compared to those who were previously treated with other monotherapies.

A total of 359 dialysis patients were treated with Fosrenol as monotherapy and were available for analysis from this multi-center, open label study, following a switch from their previous binder therapy.

More than 40% of patients were previously on combination phosphate binder therapy (two or more binders), according to a news release.

The study found that at 12 weeks of Fosrenol monotherapy, patients' mean serum phosphate levels were 1.84 mmol/L compared with 1.99 mmol/L on other previously received phosphate binding therapies.

In addition, there was an increased percentage of patients who reached K/Doqi targets. The study also demonstrated that Fosrenol was well-tolerated throughout.

Shire is a global specialty pharmaceutical company based in Basingstoke, England.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.